Open AccessSwitching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report
Author(s) -
Sakai Shintaro,
Morimoto Yoshiro,
Matsuzaka Yusuke,
Nakano Takeshi,
Kanegae Shinji,
Imamura Akira,
Ozawa Hiroki
Publication year - 2021
Publication title -
neuropsychopharmacology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.661
H-Index - 13
ISSN - 2574-173X
DOI - 10.1002/npr2.12200
Subject(s) - tardive dyskinesia , transdermal patch , transdermal , dyskinesia , medicine , pharmacokinetics , haloperidol , antipsychotic , schizophrenia (object oriented programming) , pharmacology , anesthesia , side effect (computer science) , psychiatry , dopamine , computer science , parkinson's disease , disease , programming language
Tardive dyskinesia (TD) is a common side effect of antipsychotics, and it remains a persistent and challenging problem. The blonanserin transdermal patch, developed in Japan and launched in September 2019, is the first antipsychotic transdermal treatment. Here, we describe a patient with schizophrenia who exhibited markedly improved orofacial dyskinesia after switching from blonanserin tablets to blonanserin transdermal patches. We speculate that the patch formulation might have led to more stable plasma blonanserin levels, thus reducing the side effects. Specifically, the patch formulation might have contributed to stable plasma levels via the continuous and direct absorption of blonanserin through the skin.